Coric Vlad 4
4 · Veradermics, Inc · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
Veradermics (MANE) Director Vlad Coric Buys $2.0M; Preferreds Convert
What Happened
- Vlad Coric, a director of Veradermics, acquired 58,823 shares twice (total 117,646 shares) in open-market purchases on February 5, 2026 at $17.00 per share, paying $999,991 each time (total cash ~$1,999,982).
- On February 5, 2026, multiple Series A/B/C convertible preferred share holdings automatically converted into common stock on a 10.067-for-1 basis immediately prior to the company’s IPO (no additional consideration). Those conversions resulted in approximately 638,262 common shares being issued to Coric (derivative securities disposed and common stock acquired entries).
- Coric was also reported as acquiring 51,525 shares as a grant/award on February 3, 2026 (recorded at $0.00); this award appears subject to vesting (see footnote F6: fully vested/exercisable on Feb 3, 2027).
- In total, the filing shows Coric acquired roughly 807,433 common shares across the conversions, award and open-market purchases (net of the converted derivative securities).
Key Details
- Dates: Award recorded Feb 3, 2026; conversions and open-market purchases on Feb 5, 2026. Filing date: Feb 5, 2026 (timely).
- Purchase price: $17.00 per share for the two open-market purchases (58,823 shares each); total cash spent ≈ $1,999,982.
- Conversions: Series A/B/C preferred automatically converted 10.067-for-1 into common stock immediately prior to the IPO (no cash paid; no expiration).
- Award/vesting: 51,525-share award noted Feb 3, 2026; footnote F6 says option fully vests/exercisable on Feb 3, 2027.
- Shares held via trusts: some holdings reported as held by Vladimir Coric Family Trust 2013 and Vladimir Coric Marital Trust 2013 (footnotes F2, F3).
- Ownership after transaction: the filing excerpt provided does not state the insider’s total shares outstanding owned following these transactions.
Context
- The open-market purchases are a straightforward cash purchase (bullish signal in that the insider paid market price) totaling about $2.0M. Automatic conversions of preferred into common are a structural change tied to the IPO, not an active buy or sell decision.
- The award is subject to a one-year vesting/exercise schedule per footnote F6; that means those shares are not immediately free of vesting conditions.
- These filings are factual disclosures of insider activity; they do not explain the insider’s motivations.
Insider Transaction Report
Form 4
Veradermics, IncMANE
Coric Vlad
Director
Transactions
- Conversion
Common Stock
[F1][F2]2026-02-05+33,706→ 33,706 total(indirect: See Footnote) - Conversion
Common Stock
[F1][F3]2026-02-05+33,706→ 33,706 total(indirect: See Footnote) - Conversion
Common Stock
[F4][F2]2026-02-05+148,794→ 182,500 total(indirect: See Footnote) - Conversion
Common Stock
[F4][F3]2026-02-05+148,794→ 182,500 total(indirect: See Footnote) - Conversion
Common Stock
[F5][F2]2026-02-05+78,075→ 260,575 total(indirect: See Footnote) - Conversion
Common Stock
[F5][F3]2026-02-05+78,075→ 260,575 total(indirect: See Footnote) - Conversion
Common Stock
[F5]2026-02-05+117,112→ 129,939 total - Purchase
Common Stock
[F2]2026-02-05$17.00/sh+58,823$999,991→ 319,398 total(indirect: See Footnote) - Purchase
Common Stock
[F3]2026-02-05$17.00/sh+58,823$999,991→ 319,398 total(indirect: See Footnote) - Conversion
Series A Convertible Preferred Stock
[F1][F2]2026-02-05−33,706→ 0 total(indirect: See Footnote)→ Common Stock (33,706 underlying) - Conversion
Series A Convertible Preferred Stock
[F1][F3]2026-02-05−33,706→ 0 total(indirect: See Footnote)→ Common Stock (33,706 underlying) - Conversion
Series B Convertible Preferred Stock
[F4][F2]2026-02-05−148,794→ 0 total(indirect: See Footnote)→ Common Stock (148,794 underlying) - Conversion
Series B Convertible Preferred Stock
[F4][F3]2026-02-05−148,794→ 0 total(indirect: See Footnote)→ Common Stock (148,794 underlying) - Conversion
Series C Convertible Preferred Stock
[F5][F2]2026-02-05−78,075→ 0 total(indirect: See Footnote)→ Common Stock (78,075 underlying) - Conversion
Series C Convertible Preferred Stock
[F5][F3]2026-02-05−78,075→ 0 total(indirect: See Footnote)→ Common Stock (78,075 underlying) - Conversion
Series C Convertible Preferred Stock
[F5]2026-02-05−117,112→ 0 total→ Common Stock (117,112 underlying) - Award
Stock Option (Right to Buy)
[F6]2026-02-03+51,525→ 51,525 totalExercise: $17.00Exp: 2036-02-03→ Common Stock (51,525 underlying)
Footnotes (6)
- [F1]On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F2]Shares held by Vladimir Coric Family Trust 2013.
- [F3]Shares held by Vladimir Coric Marital Trust 2013.
- [F4]On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F5]On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F6]This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.
Signature
/s/ Michael Greco, Attorney-in-Fact|2026-02-05